Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ex might recall when PPHM had a mysterious one women poster / blogger too who touted the company for a year or so. She was the talk of the PP board for a while. I can't recall her name anymore??
I KNOW, and I keep wondering why? That whopping amount of shares are the difference between being able to raise enough cash for a trial...keep the lights on without another authorized increase, instead of just handing them over to a failing management that "shareholders" seem to reward for some reason.
>>You seem more interested than anyone else,
Anyone know the status of the true-up court decision?
Yes, I've seen it many times. Btw, EC's @0 @five years seems like total nonsense.
JAMA is only a paper where the authors appear to agree L is showing some efficacy. Nothing at all to do with the regulators threshold for approval let alone payment policy.
Oh it's coming!!! Likely rent increase to Advent in 2025. LOL
>>After 12 friggin years in this mismanaged company it's time to say" SHOW ME THE MONEY HONEY"
None which LP has made any headway with in America even after twenty years.
>>Drug prices are primarily determined by market dynamics, including competition, production costs, and negotiations between manufacturers, insurers, and healthcare providers. In some cases, government policies and programs may also affect pricing.
This is a worthwhile article to get a feel for coverage and cost. The FDA allowed the Plll crossover and is willing to pay $500k annually for the tablet, but in a subset only of a rare disease.
>>Surgery is the first-line of treatment, but if these brain cancers develop into high-grade gliomas, treatment options are limited to radiation and chemotherapy — both of which introduce a range of adverse effects.
https://medcitynews.com/2024/08/brain-cancer-glioma-fda-approval-servier-pharmaceuticals-vorasidenib-voranigo/
"Or Not" should be the tittle of your book of floppers. LOL!
Oh please. Just take the FDA out the equation. That relationship seems damaged beyond repair, for whatever reason. LP can't even say their name.
The Shill metric.
>>I use different metric to evaluate the management.
Can't make it up.
"Woodford-shaped problem for her."
How's that all work exactly?
>>It unnerved her because a major investor might have created another Woodford-shaped problem for her.
Translation -They're good at building private CDMO's while letting their shareholders languish.
>>I don’t think I’m being overly generous here. It makes no sense to say they’re bad at running a company while being good at commercializing immunotherapy at scale.
Translation - Material events reporting out the window!
>>I’ll forgive the obfuscation, delays, and even dishonesty if it’s all in service of a bigger narrative that we just can’t fully see yet.
PS- waiting on the combo wasn't Flipper's narrative. I said it too just that I expected they'd need to come clean and tell investors.
But even if the combo shows real efficacy there's still the cost issue hurdle.
Could've had a nice article like this but they passed on it AGAIN.
https://www.oncologynewscentral.com/article/after-astounding-survival-results-in-sclc-updated-data-raise-question
Btw,
>>“Cisplatin is our long-held standard for limited-stage small-cell lung cancer. We would often reserve carboplatin for patients who were not robust enough for cisplatin, patients who had comorbidities, impaired renal function, so one might suspect that, in the cisplatin arm, we might see younger patients with better performance status, and that’s exactly what we do see,” he said.
Is that why they're not there because she's afraid of bumping into Adam?
New STAT News article out!
"After 10 years of game-changing immunotherapies, a cancer conference celebrates — and sees more work to do"
>>The annual ESMO meeting featured gratitude and also debate"
They don't have much left to dilute. Look for a reverse split with a new batch of authorized or perhaps they fold and private Advent "buys" NWBO's IP.
>>Dilution is going to be nonstop and the only certain thing that is going to happen.
After that last post about "Fabulous" I'd be careful who you call a dummy.
If the science is really that good and management this bad, it should upset shareholders even more.
Forgot to add that nobody except for a few disciples here has seen for years. I think it may be the mystique that adds to the "obsession".??
>>Yeah, why are you so obsessed with the CEO CFO COB COBK COC and a bunch of other tittles Doc says the One women show runs under!!!
Best beach weeks are right after the summer, IMO.
Seems like everyone on the Street knows exactly what's going on even as poor retail prefer to live in fantasy.
I had hoped that even just one of the disciples would put up my post on Bigger's X account because they want to know too. But no.
Secretly I think they do like it. Some kind of hostage syndrome.
Dear Mr. Bigger,
Since your big X announcement in 2022 of being "Long 30,000,000", the share price has been cut by more than half. You haven't been chiming in much lately except to criticize the CEO CFO on her lack of providing a plan. Will you please quickly confirm in a filing that you still have your 30M or at least have some ownership. Thanks.
Yeah, why are you so obsessed with the CEO CFO COB COBK COC and a bunch of other tittles Doc says the One women show runs under!!!
Still can't find a mention of him unless it's connected to that NWBO PR.
>>Dr. Duffy's roles included scientific support and outreach to health care providers and national and regional scientific leaders in over 20 different solid tumors and hematologic malignancies (blood cancers and lymphomas) relating to Merck's clinical development and commercialization of Keytruda, as well as ongoing scientific support for Merck's Investigator-Initiated Study Program. He served as the national contact point between the scientific affairs team in the field and the internal R&D team in Merck for studies in first-line non-small cell lung cancer, triple negative breast cancer and ER+/HER2- breast cancer, and metastatic prostate cancer.
https://www.contractpharma.com/contents/view_breaking-news/2019-09-04/northwest-biotherapeutics-expands-senior-management-team/
If you call Advent and ask to speak to LP you might catch her.
NWBO not showing up to this even either.
>>Approximately 90% of patients experience GBM tumor recurrence at or near the original tumor location, yet there are no FDA-approved treatments in the recurrent or progressive setting that can significantly extend a patient’s life.
>>ReSPECT-GBM is supported by an award from the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), and ReSPECT-LM is funded by a three-year $17.6M grant by the Cancer Prevention & Research Institute of Texas (CPRIT).
https://www.globenewswire.com/news-release/2024/09/18/2948117/0/en/Plus-Therapeutics-Showcases-New-Interim-ReSPECT-GBM-Phase-2-Trial-Data-at-the-2024-Congress-of-Neurological-Surgeons-Annual-Meeting.html
Yup, end of conversation. A full day on the topic of insider holdings and nothing learned.
LP could've set it up so some billionaire pays for Specials treatments while investing in NWBO at these "low ball" share prices. But no.
Advent is now beyond the seven years since LP took it over so unsure how it ever gets clawed back.
Can't make it up if you tried.
"Linda is managing everything"
Even when you present the disciples with a strategy to help support the share price they fight with you. LOL
Just more of the usual disciple nonsense to cutoff the conversation.
What's factually correct? Do you see anywhere the number of shares or $ that were invested?
Just like with the Duff, Insider holdings is information the disciples should have at their fingertips to help support the stock. The company should be bending over backwards to supply that information given their lack of institutional holdings. But instead nothing. Sorry folks, but this is all just common sense.
LP has diluted EVERYONE out of the need to file.